Introduction
Different types of protein modifications are used to fine-tune protein activity in such a way that the biological processes in the cell are executed as intended. Errors in the regulation of protein activity may result in malignant transformation. Since the discovery of ubiquitylation more than 20 years ago, it has become clear that protein modification with ubiquitin is a very important post-translational regulation mechanism. Different types of protein modifications by ubiquitin exist and can regulate protein activity in different ways. Some types of ubiquitylation may result in altering the biological function of proteins, whereas other forms of ubiquitin modifications result in the specific degradation of proteins by the 26S proteasome. In this manner, the ubiquitin proteasome system (UPS) regulates several important biological processes like cell division, apoptosis and differentiation. 1 In this review, the different forms of ubiquitylation and their role during hematopoiesis will be discussed. In addition, novel therapies targeting the UPS in hematopoietic malignancies will be highlighted.
Ubiquitylation
Ubiquitin is a conserved, small peptide (76 amino acids) that can be coupled to substrate proteins in a three-step enzymatic cascade. This cascade starts with the activation of free ubiquitin by the ubiquitin-activating enzyme (E1) through an ATPdependent reaction (Figure 1a ). During the second step, the activated ubiquitin is transferred to ubiquitin-conjugating enzymes (E2). Finally, through a functional interaction with E2 enzymes, ubiquitin ligases (E3) recognize specifically substrates and facilitate the conjugation of ubiquitin to a lysine residue of the target proteins. Therefore, the specificity of the UPS is determined by the E3 ligases. 2 The large number and variety of proteins regulated by ubiquitylation demands high specificity and accounts for the number of different E3 ligases encoded by our genome as is depicted in Figure 1a . The more general steps of the UPS are carried out by a smaller number of proteins. At this moment, only one E1 and approximately 30 E2 enzymes are known. 3, 4 E3 ligases can be subdivided into different classes based on activity and structural domains. One group of E3 enzymes has ubiquitin ligase activity by itself like proteins that contain RING finger, HECT or U-box domains. The other group of E3 proteins feature only E3 ligase activity when complexed with other proteins. These proteins like the suppressor of cytokine signaling (SOCS)-box, F-box and cullin proteins play a role in the recognition of substrates. 1 
Different kinds of ubiquitin modifications: different functions
During protein ubiquitylation, the C-terminal glycin residue of ubiquitin is conjugated to lysine residues within substrate proteins. Proteins can be modified with ubiquitin in various ways (Figure 1b) . If only one ubiquitin moiety is coupled to a protein, this is called monoubiquitylation. Different types of growth factor receptors are monoubiquitinated. This results in receptor internalization followed by recycling of the receptor to the cell membrane or by transport to lysosomes where these receptors are degraded by proteases. 5 Many proteins can also be modified with polyubiquitin chains. The covalent coupling of one ubiquitin to a preceding ubiquitin takes place on one of the seven lysines (at positions 6, 11, 27, 29, 33, 48, 63) of ubiquitin ( Figure 1b ). Polyubiquitin chains linked via different lysines of ubiquitin take on different structures resulting in a different fate of the ubiquitinated proteins. Polyubiquitylation of proteins linked via lysine 63 (K63) results in functional modulation of the substrate as has been shown for several proteins involved in DNA repair, [6] [7] [8] [9] transcriptional regulation 10 or signal transduction. 11, 12 The most common type of polyubiquitylation is characterized by chains linked through lysine 48 (K48) of the preceding ubiquitin. Proteins supplied with a K48-or K29-linked ubiquitin chain are specifically recognized by the 26S proteasome. The function of polyubiquitin chains linked via K6, K11 or K33 remains poorly understood. Despite the potential for enormous complexity of polyubiquitin chains owing to the use of different lysines in one polyubiquitin chain (mixed chains), it is assumed that within one chain the ubiquitin moieties are linked through the same lysine. 13 
Protein degradation by the 26S proteasome
When a substrate protein is marked with four or more ubiquitin peptides linked via K48, this complex can be recognized by the 26S proteasome resulting in active degradation of the marked protein. The 26S proteasome consists of a 19S and 20S component 14, 15 and is localized both in the nucleus and cytoplasm. The 20S core of the proteasome has the shape of a barrel consisting of four rings each containing seven proteins ( Figure 2) activity is localized inside this barrel-like structure, proteins outside the proteasome are protected against its proteolytic activity. The 20S core has a 19S regulatory cap on both ends, which are responsible for recognition, deubiquitylation, unfolding and internalization of polyubiquitinated proteins. 16 Mammals also have another regulatory complex that, instead of the 19S complex, can associate with the 20S proteasome: 11S (PA28). This complex contains the PA28a and PA28b subunits whose expression is induced by interferon-a. Accumulating evidence suggests that the 11S regulatory complex plays a role in the production of antigenic peptides for presentation by major histocompatibility class 1 molecules.
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Deubiquitylation
The ubiquitylation of proteins is a reversible process. Deubiquitinating proteins (DUBs) can remove covalently attached ubiquitin from substrate proteins, through cleavage of single ubiquitin moieties or chains from the substrate or from a preceding ubiquitin molecule. The human genome encodes for approximately 80 DUBs. 19 These DUBs abolish the effect of E3 ligases by removing the ubiquitin from substrate proteins, which may prevent their degradation. Another essential role for DUBs is the removal of ubiquitin from ubiquitinated proteins in the 19S part of the proteasome (Figure 2 ), resulting in re-usable free ubiquitin. 4, 19 Recently, specific DUBs have been implicated in hematopoiesis. For example, a murine DUB family was found to be induced after cytokine exposure in hematopoietic cells. Of this family, DUB-1 is rapidly induced after stimulation with interleukin (IL)-3 or granulocyte-macrophage colony-stimulating factor, whereas DUB-3 is induced with IL-4 and -6 in different hematopoietic cells. DUB-2 is regulated specifically by IL-2 in T cells. The expression of DUB-2 can inhibit apoptosis owing to cytokine redrawal. 20 DUB-3 blocks the proliferation of murine Ba/F3 and NIH3T3 cells. 21 Recently, the DUB USP42 was identified in a translocation with RUNX1 in acute myeloid leukemia (AML). 22 Its involvement in this translocation suggests that deregulation of ubiquitin-associated pathways may be important in leukemogenesis.
NF-jB signaling: an example of an UPS-regulated pathway
An example in which the UPS regulates the activity of a biological pathway at several levels by (de) ubiquitylation and proteasomal degradation is the nuclear factor kappa B (NF-kB) pathway. NF-kB is a transcription factor that regulates the expression of several genes involved in proliferation, apoptosis and immunity. In the inactive form, NF-kB is localized in the cytoplasm. In order to regulate genes in the nucleus, NF-kB needs to be released from its interactor IkB. This inhibitor keeps NF-kB inactive in the cytoplasm. Upon activation of, for example, the IL-1 receptor, signal-transduction proteins are recruited to the intracellular part of the receptor (Figure 3a) . One of these proteins, tumor necrosis factor receptor associated factor (TRAF)6, is subsequently autoubiquitinated upon receptor binding with ubiquitin chains linked via K63. The ubiquitylation of TRAF6 is controlled by the DUBs CYLD and A20, which can remove the ubiquitin of TRAF6 and as a consequence inhibit the NF-kB route. [23] [24] [25] The K63 ubiquitin chain on TRAF6 does not target this protein for proteasomal degradation, but is essential for the recruitment of proteins that phosphorylate downstream kinases. These downstream kinases (the inhibitor of kappa B kinase (IKK) complex) are responsible for the phosphorylation of IkB. The phosphorylated form of IkB is specifically recognized by an E3 ligase complex Skp1/cullin/Fbox-btransducin repeat (SCF-bTrCP) that ubiquitylates IkB via K48 (Figure 3b ). This results in the 26S proteasomal degradation of IkB, resulting in the release of NF-kB from its inhibitor and the translocation to the nucleus where NF-kB can be active to regulate genes. 11 In B cells, NF-kB can be activated upon activation of the TNF receptor family by the 26S proteasome in a different manner. In this case, the IKKa complex phosphorylates p100, a precursor of the p52 subunit of NF-kB. The precursor is normally inactive as it is retained in the cytoplasm. Upon phosphorylation, the p100 protein is polyubiquitylated and processed, but not completely degraded, by the 26S proteasome. The p100 protein is partially degraded resulting in an active mature p52 subunit, which translocates to the nucleus where it can be active.
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Ubiquitylation and protein degradation in normal hematopoiesis
Ubiquitylation and proteasomal degradation play a crucial role during various important biological processes. During hematopoiesis it is involved in the control of proliferation, differentiation and apoptosis. Several proteins involved in blood cell development are known to be regulated by the UPS. 28 Examples are the growth factor receptor c-kit , cyclin D, 29 the antiapoptotic protein Bcl-2 30 and the transcription factors AML1, 31 GATA-2, 32 CCAAT/enhancer-binding protein-a 33 and Gfi1. 34 Although it is known that these proteins are degraded via the UPS for the majority, the responsible ubiquitin E3 ligase are not known. So far, some E3 ligases were shown to play a role in hematopoietic cells. For example the ubiquitin ligase Triad1. The Triad1 mRNA and protein levels are induced specifically during myeloid cell differentiation. Overexpression of Triad1 resulted in an inhibition of clonogenic growth of murine bone marrow cells (colony-forming units granulocyte-macrophage).
As the ubiquitin ligase activity of Triad1 was essential to these processes, this showed that the UPS can play an important during myelopoiesis. 35 Another member of the TRIAD family of E3 ligases, Triad3, was shown to catalyze the ubiquitylation of the Toll-like receptors TLR4 and 9. This results in the proteasomal degradation of these receptors. In this way, Triad3 controls the intensity and duration of TLR signaling, thereby playing an important role during innate immunity. 36 Cullin 4A (Cul4A) is an example of an essential subunit in a specific RING finger E3 ligase complex. Cul4A was found to interact directly with HoxA9 and together with the complete E3 complex to ubiquitylate this homeodomain transcription factor. HoxA9 is a key regulator of hematopoiesis and is expressed in primitive cells and downregulated upon granulocytic differentiation. The Cul4A-mediated degradation of HoxA9 may play an important role during the differentiation of granulocytes, influencing Cul4A expression has direct effect on granulocytic differentiation. 37, 38 The UPS also plays an essential role in the attenuation of receptor signaling after their activation in hematopoietic cells. An example is the SOCS proteins. By binding specifically to activated growth factor receptors, SOCS proteins recruit E3 ligase complexes to these receptors. These complexes ubiquitylate the activated receptor, which results in the proteasomal degradation or internalization of the receptor. Together with the E3 complexes, the SOCS proteins are responsible for the After activation by phosphorylation of TAK1, the IKK complex is activated, which results in the phosphorylation of IkB. This is the signal for the E3 ligase complex (SCF-bTrCP) to ubiquitylate IkB with chains linked via K48, resulting in the proteasomal degradation of the inhibitor of NF-kb. Unbound NF-kB is translocated to the nucleus where it functions as transcription factor to activate genes. Another manner by which NF-kB can be activated is by partial protein degradation. After phosphorylation by IKKa, the p100 precursor is polyubiquitylated. The 26S proteasome mediates the maturation of the p100 into the active, mature p52 NF-kB subunit, which translocates to the nucleus.
attenuation of the signal after receptor stimulation. 39, 40 Another protein regulating the activity of receptors is CBL. This protein is a negative regulator of a number of activated tyrosine kinase receptors like the colony stimulation factor-1 receptor (CSF1R), the platelet-derived growth factor (PDGF) receptor and the stem cell factor (SCF) receptor c-kit. After receptor activation, Cbl catalyses the ubiquitylation of these receptors. This ubiquitylation results in receptor internalization and lysosomal targeting where these receptors are degraded by proteases. 41 In this way, Cbl prevents the receptors from remaining constitutively active, which can result in oncogenic transformation. 41, 42 Altered ubiquitylation and malignant hematopoiesis Alterations in ubiquitylation may contribute to the onset of malignant transformation. 43 Due to mutations or misexpression, the UPS can be disturbed. Three common types of alterations in the UPS will be discussed that may occur in hematopoietic malignancies. Discussed alterations are: (I) mutations in ubiquitin E3 ligases, resulting in impaired ubiquitylation of their substrate, (II) misexpression of E3 ligases, resulting in altered ubiquitylation of substrates and (III) mutations in substrates, which makes them insensitive for the activity of the UPS. When ubiquitin ligases are inactivated by genetic defects, this results in diminished ubiquitylation of their respective substrate proteins, which subsequently can result in malignancies. This is illustrated by inactivating mutations in the Von Hippel-Lindau (VHL) E3 ubiquitin ligase, which can be detected in patients with congenital polycythemia. These mutations result in defective ubiquitylation and subsequent stabilization of its substrate hypoxia inducible factor (Hif)1a (Figure 4a ). Hif1a is a transcription factor and its stabilization results in an increased expression of erythropoietin. It is assumed that increased erythropoietin expression levels contribute to the onset of this form of polycythemia. 44 Another example in which the E3 ligase is inactivated is Fanconi anemia (FA). FA is characterized by chromosomal instability and a correlated predisposition to malignancies like AML. Normally, after DNA damage, Fanconi anemia D2 (FANCD2) is monoubiquitinated, which results in the relocalization of FANCD2 to damaged DNA for repair. A complex of multiple FA proteins is responsible for the monoubiquitylation of FANCD2 (Figure 4b) . In patients suffering from FA, mutations are found in one of these FA proteins. The mutations prevent the proper monoubiquitylation of FANCD2 and thereby inhibit the FANCD2 initiated DNA repair. 45 Recently also, a DUB for FANCD2 was identified, which deubiquitinates FANCD2 after the DNA damage is repaired. 46 Mutations resulting in misexpression of E3 ligases have also been described. If the substrate proteins are tumor suppressors or proapoptotic proteins, this can result in oncogenic transformation. One example is the ubiquitin ligase MDM2, which ubiquitinates and targets the tumor suppressor p53 for proteasomal degradation. In about 70% of all leukemias, MDM2 is overexpressed when compared to non-malignant cells, 47 for example as a result of gene amplifications. 48 Overexpression of MDM2 results in the constitutive ubiquitylation and subsequent degradation and inactivation of p53 (Figure 4c ). Inactivation of p53 is often a hallmark of oncogenic transformation. A comparable mechanism in which p53 is inhibited is found in leukemias characterized by the AML1-eight twenty-one (ETO) fusion protein. AML1-ETO specifically represses the p14 arf protein. 49 p14 arf normally interacts with MDM2, thereby neutralizing the interaction of MDM2 with p53. 50 The downregulation of p14 arf in AML1-ETO-positive leukemias may result in increased MDM2 activity and increased degradation of p53.
Finally, mutations in substrate proteins may result in inhibition of their ubiquitylation when they are no longer recognized by E3 ligases. An example is point mutations in the c-myc oncogene, which are found in lymphoma's. The c-myc oncogene encodes a short-lived transcription factor that plays an important role in cell cycle regulation, differentiation and apoptosis. Mutations in c-myc results in diminished phosphorylation of c-myc. The SCF E3 ligase complex of c-myc recognizes only the phosphorylated form of c-myc (Figure 4d) . As a consequence, mutated c-myc is no longer ubiquitinated by SCF, resulting in the stabilization and accumulation of the oncoprotein c-myc, 51 which might be one of the steps necessary for the onset of lymphoma's.
The UPS as a novel therapeutic target
As changes in ubiquitylation and subsequent alterations in function or turnover of substrate proteins have been implicated in the onset of hematological malignancies, the UPS is a new potential therapeutic target. One of the targets is the 26S proteasome itself. Proteasome inhibition results in growth inhibition and apoptosis of multiple myeloma (MM) cells, whereas wild-type cells are less sensitive. 52 A recently published phase III study showed that treatment with the proteasome inhibitor Velcade is more successful for the treatment of refractory MM than the standard treatment with dexamethasone. 53 Proteasome inhibition results in stabilization of substrate proteins, which normally would have been degraded by the proteasome (Figure 5a) . Recently, other proteasome inhibitors than Velcade were shown to induce apoptosis also in Velcaderesistant MM cells. 54 It is assumed that the apoptotic effect of Velcade is caused by the stabilization of proapoptotic proteins, for example, by abrogating the degradation of IkB, thereby inhibiting the activation of the transcription factor NF-kB (Figure 3b ). 55 However, recent studies showed that MM cells are far more sensitive to proteasome inhibitors than to IkB kinase inhibitors, suggesting that NF-kB is not solely responsible for the observed increase of apoptosis. MM cells produce large amounts of antibodies, also resulting in large amounts of misfolded proteins. When misfolded proteins cannot be correctly refolded, they are targeted for endoplasmatic reticulum-associated protein degradation (ERAD), which involves the activity of the 26S proteasome. 56 After proteasome inhibition, these unfolded protein accumulate and induce an unfoldedprotein response that may result in subsequent cell cycle arrest and apoptosis. 57 Another theory is that during the late phase of plasma cell differentiation, the proteasome activity is decreased owing to the massive amount of Ig production, thereby making these cells more sensitive for proteasome inhibition. 58 Both hypotheses could explain why MM cells are especially sensitive for treatment with proteasome inhibitors.
Mdm2
While clinical outcomes with proteasome inhibitors are promising, 59 ,60 this type of therapy does not target specific proteins and therefore may affect all proteins, which are normally degraded. The recent identification of specific alterations in ubiquitin E3 ligases provide very specific targets for novel inhibitors instead of reducing the activity of the complete 26S proteasome. 61 A well-characterized example is the MDM2-mediated ubiquitylation and subsequent degradation of the tumor suppressor p53. As described above, several tumors are characterized by MDM2 amplification resulting in constitutive degradation and inactivation of p53. Recently, small molecule antagonists of MDM2 (nutlins) were identified, which specifically disrupt the interaction with p53 by binding to the p53-binding domain of MDM2 (Figure 5b ). The treatment of MDM2-overexpressing cell lines and in vivo tumor models with nutlins resulted in the activation of p53 and subsequent inhibition of proliferation and induction of apoptosis. 62 This therapy can only be effective when p53 is not mutated as stabilization of mutated p53 is not beneficial. In contrast to other tumors, the majority of patients suffering from leukemia have wild-type p53. In vitro tests showed that treatment of both AML 63 as well as B-CLL 64 cells with nutlins resulted in p53-mediated apoptosis. Thus, nutlins may be promising new drugs especially for the treatment of hematological cancers.
In the past years, several aberrancies in the UPS were identified, which play an important role in cancer development including hematopoietic malignancies. Besides the use of a general intervention of the UPS by proteasome inhibitors, novel therapies that specifically disrupt E3 ligase-substrate interactions are being tested. This shows that inhibition of ubiquitylation is a very powerful tool to modify the activity of proteins and makes the UPS a very interesting therapeutic target. During hematopoiesis, various important proteins are subject to ubiquitylation. However, most of the responsible ubiquitin E3 ligases are still unknown. The human genome encodes for 700 proteins with domains implicated in the UPS. It is important to broaden our knowledge of these genes during normal and malignant hematopoiesis to identify novel specific, drugable targets.
